

OCT 27 1999

GROUP 1600
Attorney Docket No.: 3556.224-US

OFFICIAL

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Uffe Loeborg

Serial No.: 09/056,343

Group Art Unit: 1652

Filed: April 7, 1998

Examiner: W. Moore

For: Proteins with Changed Epitopes and Methods for the Production Thereof

FILING OF CONTINUED PROSECUTION
APPLICATION (CPA) UNDER 37 C.F.R. §1.53(d)Assistant Commissioner for Patents
Box CPA
Washington, DC 20231

This is a request for filing a continuation application under 37 CFR 1.53(d) of prior application number 09/056,343 filed on April 7, 1998 entitled Proteins with Changed Epitopes and Methods for the Production Thereof.

1. [x] The filing fee is calculated as follows:

Basic Fee:	\$760.00
Total Claims: 23 - 20 = 3 x18 =	\$ 54.00
Independent Claims: 2 - 3 = 0 x78 =	\$ 0
Total Fee:	\$814.00

2. Applicant hereby petitions for an extension of time under 37 CFR 1.136 for 3 months. If an additional extension of time is required, please consider this a petition therefor. The required extension fee is estimated to be \$870.

3. [x] Please charge the required fee, estimated to be \$1684, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is

10/29/1999 LPENDER 141447 09056343

01 FC:117
02 FC:131
03 FC:103

870.00 CH
760.00 CH
Date: October 26, 1999

Respectfully submitted,



Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

OCT 27 1999

OFFICIAL

Attorney Docket No.: 3556.224-US

GROUP 1600 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Uffe Loevborg

Serial No.: 09/056,343

Group Art Unit: 1652

Filed: April 7, 1998

Examiner: W. Moore

For: Proteins with Changed Epitopes and Methods for the Production Thereof

CERTIFICATE OF FACSIMILE TRANSMISSION

Assistant Commissioner for Patents
Box CPA
Washington, DC 20231

Re: Continued Prosecution Application of
Serial No. 09/056,343

Sir:

I hereby certify that the attached correspondence comprising:

1. Filing of Continued Prosecution Application (CPA) under 37 C.F.R. §1.53(d) (in duplicate)

was sent to the United States Patent Office by telefax to the attention of Examiner W. Moore, fax number (703) 308-4556.

Date: October 26, 1999

Respectfully submitted,



Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

FAX RECEIVED

OCT 27 1999 NOVO NORDISK OF NORTH AMERICA, INC.
GROUP 1600 405 LEXINGTON AVENUE, SUITE 6400
NEW YORK, NEW YORK 10174-6401

OFFICIAL

Telephone: (212) 867-0123

FAX: (212) 878-9655

CORPORATE PATENTS

TELECOPY

Page 1 Of 4 Page(s)

Serial # 09/056,343

Please Hand Deliver The Following To:

TO : Examiner W. Moore TECHNICAL CENTER 1600
Group 1800 Fax # (703) 308-4556

CC : _____

FROM : Elias T. Lambiris, Esq., Reg. No. 33,728

DATE : October 26, 1999

MESSAGE : _____

IF ANY PROBLEMS OCCUR, PLEASE CALL
LOREN HERNANDEZ (212) 867-0123
Fax. (212) 878-9655

The information contained in this facsimile message is legally privileged and confidential information intended solely for the use of the persons or entities named below. If you are not such persons or entities, you are hereby notified that any distribution, dissemination or reproduction of this facsimile message is strictly prohibited. If you have received this message in error, please immediately call us collect at the above number.